EP2000534A3 - Nukleinsäureliganden Gewebezielverbundenen Anwendungen - Google Patents

Nukleinsäureliganden Gewebezielverbundenen Anwendungen Download PDF

Info

Publication number
EP2000534A3
EP2000534A3 EP08012656A EP08012656A EP2000534A3 EP 2000534 A3 EP2000534 A3 EP 2000534A3 EP 08012656 A EP08012656 A EP 08012656A EP 08012656 A EP08012656 A EP 08012656A EP 2000534 A3 EP2000534 A3 EP 2000534A3
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
acid ligands
cells
ligands
related applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08012656A
Other languages
English (en)
French (fr)
Other versions
EP2000534A2 (de
Inventor
Andrew Stephens
Daniel J. Schneider
Larry Gold
Ulrich Dr. Speck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Gilead Sciences Inc
Original Assignee
Bayer Schering Pharma AG
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,124 external-priority patent/US5750342A/en
Priority claimed from US08/433,126 external-priority patent/US5688935A/en
Application filed by Bayer Schering Pharma AG, Gilead Sciences Inc filed Critical Bayer Schering Pharma AG
Publication of EP2000534A2 publication Critical patent/EP2000534A2/de
Publication of EP2000534A3 publication Critical patent/EP2000534A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP08012656A 1995-05-03 1996-05-01 Nukleinsäureliganden Gewebezielverbundenen Anwendungen Withdrawn EP2000534A3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/433,124 US5750342A (en) 1990-06-11 1995-05-03 Nucleic acid ligands of tissue target
US08/433,126 US5688935A (en) 1990-06-11 1995-05-03 Nucleic acid ligands of tissue target
EP96915422A EP0824540B1 (de) 1995-05-03 1996-05-01 Nukleinsäureliganden für gewebeziele
EP04015822A EP1564290B1 (de) 1995-05-03 1996-05-01 Verfahren zur Identifizierung von Nukleinsäureliganden für Gewebsziele

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP04015822A Division EP1564290B1 (de) 1995-05-03 1996-05-01 Verfahren zur Identifizierung von Nukleinsäureliganden für Gewebsziele

Publications (2)

Publication Number Publication Date
EP2000534A2 EP2000534A2 (de) 2008-12-10
EP2000534A3 true EP2000534A3 (de) 2009-09-02

Family

ID=27029755

Family Applications (3)

Application Number Title Priority Date Filing Date
EP96915422A Expired - Lifetime EP0824540B1 (de) 1995-05-03 1996-05-01 Nukleinsäureliganden für gewebeziele
EP08012656A Withdrawn EP2000534A3 (de) 1995-05-03 1996-05-01 Nukleinsäureliganden Gewebezielverbundenen Anwendungen
EP04015822A Expired - Lifetime EP1564290B1 (de) 1995-05-03 1996-05-01 Verfahren zur Identifizierung von Nukleinsäureliganden für Gewebsziele

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP96915422A Expired - Lifetime EP0824540B1 (de) 1995-05-03 1996-05-01 Nukleinsäureliganden für gewebeziele

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04015822A Expired - Lifetime EP1564290B1 (de) 1995-05-03 1996-05-01 Verfahren zur Identifizierung von Nukleinsäureliganden für Gewebsziele

Country Status (9)

Country Link
EP (3) EP0824540B1 (de)
JP (1) JPH11504812A (de)
AT (2) ATE401424T1 (de)
AU (1) AU727460B2 (de)
CA (2) CA2641149A1 (de)
DE (2) DE69637605D1 (de)
DK (1) DK1564290T3 (de)
ES (1) ES2310695T3 (de)
WO (1) WO1996034874A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
WO2000043534A1 (en) * 1999-01-19 2000-07-27 Somalogic, Inc. Method and apparatus for the automated generation of nucleic acid ligands
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US8030465B2 (en) 2001-06-29 2011-10-04 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
AU2775402A (en) * 2001-06-29 2003-01-02 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
EP2078751A1 (de) * 2008-01-11 2009-07-15 Commissariat A L'energie Atomique Spezifische zur Unterdrückung der Zellmigration und -invasion durch Krebszellen erzeugte Aptamere, Verfahren zur Auswahl derartiger Aptamere und ihre Verwendung
EP2159286A1 (de) * 2008-09-01 2010-03-03 Consiglio Nazionale Delle Ricerche Verfahren zur Gewinnung von Oligonucleotid-Aptameren und Verwendungen damit
AU2014353102B2 (en) 2013-11-21 2019-05-16 Somalogic Operating Co., Inc. Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014843A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
WO1992014842A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
WO1996034875A1 (en) * 1995-05-03 1996-11-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
WO1994029479A1 (en) * 1993-06-09 1994-12-22 Pharmagenics, Inc. Oligonucleotides which inhibit hiv protease function
US20170110787A1 (en) 2015-10-14 2017-04-20 Apple Inc. Electronic Devices With Millimeter Wave Antennas And Metal Housings

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014843A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
WO1992014842A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
WO1996034875A1 (en) * 1995-05-03 1996-11-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CONKLIN BRIAN S ET AL: "Shear stress regulates occludin and VEGF expression in porcine arterial endothelial cells.", JOURNAL OF SURGICAL RESEARCH, vol. 102, no. 1, January 2002 (2002-01-01), January, 2002, pages 13 - 21, XP001107201, ISSN: 0022-4804 *
GOLD L ET AL: "DIVERSITY OF OLIGONUCLEOTIDE FUNCTIONS", ANNUAL REVIEW OF BIOCHEMISTRY, PALTO ALTO, CA, US, vol. 64, January 1995 (1995-01-01), pages 763 - 797, XP000618016, ISSN: 0066-4154 *
JELLINEK D ET AL: "INHIBITION OF RECEPTOR BINDING BY HIGH-AFFINITY RNA LIGANDS TO VASCULAR ENDOTHELIAL GROWTH FACTOR", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 34, no. 33, 30 August 1994 (1994-08-30), pages 10450 - 10456, XP001084739, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
ATE276266T1 (de) 2004-10-15
EP2000534A2 (de) 2008-12-10
AU727460B2 (en) 2000-12-14
DE69633386D1 (de) 2004-10-21
EP0824540A1 (de) 1998-02-25
ES2310695T3 (es) 2009-01-16
DE69637605D1 (de) 2008-08-28
WO1996034874A1 (en) 1996-11-07
EP0824540A4 (de) 2003-04-23
ATE401424T1 (de) 2008-08-15
DK1564290T3 (da) 2008-11-17
EP1564290A3 (de) 2006-02-01
CA2219106C (en) 2008-09-23
CA2219106A1 (en) 1996-11-07
EP1564290B1 (de) 2008-07-16
AU5720096A (en) 1996-11-21
DE69633386T2 (de) 2005-09-22
EP0824540B1 (de) 2004-09-15
EP1564290A2 (de) 2005-08-17
JPH11504812A (ja) 1999-05-11
CA2641149A1 (en) 1996-11-07

Similar Documents

Publication Publication Date Title
EP2000534A3 (de) Nukleinsäureliganden Gewebezielverbundenen Anwendungen
CA2219807A1 (en) Systematic evolution of ligands by exponential enrichment: tissue selex
CA2086672A1 (en) Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
CA2116215A1 (en) Diagnostic Applications of Double D-Loop Formation
CA2337197A1 (en) Microdevices for screening biomolecules
CA2190588A1 (en) Pteridine nucleotide analogs as fluorescent dna probes
AU6147096A (en) Use of nucleic acid ligands in flow cytometry
WO2001012659A3 (en) Human dna sequences
CA2068027A1 (en) Pharmaceutical compositions comprising an anticytokine
EP1102787A4 (de) 2'-o-aminoethyloxyethyl-modifizierte oligonukleotide
WO2000070088A3 (en) Immobilization of unmodified biopolymers to acyl fluoride activated substrates
CA2229766A1 (en) Modified primers
RU94000061A (ru) Эфиры холестерина и ненасыщенных жирных кислот, способ лечения и фармацевтическая или косметическая композиция
DE69434942D1 (de) Mehrzweckreagenzsystem zur schnellen lysierung von vollblutproben
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
CA2223078A1 (en) Nucleic acid ligands that bind to and inhibit dna polymerases
EP1378522A3 (de) Methoden um die Bioaktivität von Chemokinen zu verstärken
CA2034504A1 (en) Fungal stress proteins
WO2000069896A3 (en) Molecular interactions in haematopoietic cells
WO1996034113A3 (en) Methods for the identification of farnesyltransferase inhibitors
AU6144590A (en) Lactam-containing compositions and methods useful for the hybridization of nucleic acids
WO1991009973A3 (en) C. difficile specific oligonucleotides
CA2236837A1 (en) Detection of mammary tumor virus-like sequences in human breast cancer
CA2215745A1 (en) Human stat4
CA2013544A1 (en) Retinoblastoma gene product antibodies and uses therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080811

AC Divisional application: reference to earlier application

Ref document number: 1564290

Country of ref document: EP

Kind code of ref document: P

Ref document number: 0824540

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GOLD, LARRY

Inventor name: STEPHENS, ANDREW

Inventor name: SPECK, ULRICH, DR.

Inventor name: SCHNEIDER, DANIEL, J.

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101ALI20090505BHEP

Ipc: C07H 21/02 20060101AFI20090505BHEP

Ipc: C07H 21/04 20060101ALI20090505BHEP

Ipc: C12P 19/34 20060101ALI20090505BHEP

Ipc: C12N 15/10 20060101ALI20090505BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20100420

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101102